About Inno Therapy
Inno Therapy is a company based in Seoul (South Korea) founded in 2010 by Moon Sue Lee and Hae Shin Lee. Inno Therapy has raised $2.77 million across 2 funding rounds from investors including BSK Investment and Songhyun Investment. The company has 63 employees as of December 31, 2024. Inno Therapy operates in a competitive market with competitors including Adhezion Biomedical, HyperBranch Medical, BRIJ Medical, BORAYER and Mussel Polymers, among others.
- Headquarter Seoul, South Korea
- Employees 63 as on 31 Dec, 2024
- Founders Moon Sue Lee, Hae Shin Lee
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Scl Science Inc.
-
Annual Revenue
$3.21 M (USD)258.3as on Dec 31, 2024
-
Net Profit
-$2.53 M (USD)25.79as on Dec 31, 2024
-
EBITDA
-$1.74 M (USD)23.14as on Dec 31, 2024
-
Total Equity Funding
$2.77 M (USD)
in 2 rounds
-
Latest Funding Round
$1.83 M (USD), Seed
Jun 01, 2014
-
Investors
BSK Investment
& 1 more
-
Employee Count
63
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Inno Therapy
Inno Therapy is a publicly listed company on the KRX with ticker symbol 246960 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Inno Therapy
Inno Therapy has successfully raised a total of $2.77M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.83 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $1.8M
-
First Round
First Round
(01 Jun 2012)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2014 | Amount | Seed - Inno Therapy | Valuation | BSK Investment , Songhyun Investment |
|
| Jun, 2012 | Amount | Seed - Inno Therapy | Valuation | BSK Investment |
|
Investors in Inno Therapy
Inno Therapy has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include BSK Investment and Songhyun Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Private equity and venture capital investment fund
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inno Therapy
Financial Statements - Inno Therapy
Inno Therapy Comparisons
Competitors of Inno Therapy
Inno Therapy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adhezion Biomedical, HyperBranch Medical, BRIJ Medical, BORAYER and Mussel Polymers, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of cyanoacrylate based surgical, wound management, and infection prevention products
|
|
| domain | founded_year | HQ Location |
Biosurgical devices are developed using proprietary polymers and hydrogels.
|
|
| domain | founded_year | HQ Location |
Medical devices for post-surgical and trauma incision care are provided.
|
|
| domain | founded_year | HQ Location |
Biomaterials for surgery and wound repair are developed.
|
|
| domain | founded_year | HQ Location |
Adhesive solutions are manufactured for diverse materials and applications.
|
Frequently Asked Questions about Inno Therapy
Inno Therapy was founded in 2010 and raised its 1st funding round 2 years after it was founded.
Inno Therapy is headquartered in Seoul, South Korea.
Moon Sue Lee is the current CEO of Inno Therapy. They have also founded this company.
Inno Therapy is a funded company, having raised a total of $2.77M across 2 funding rounds to date. The company's 1st funding round was a Seed of $938.25K, raised on Jun 01, 2012.
As of Dec 31, 2024, the latest employee count at Inno Therapy is 63.
Annual revenue of Inno Therapy is $3.21M as on Dec 31, 2024.
Inno Therapy was founded in 2010 in Seoul, South Korea, and operates in the medical devices sector. Patented polymers are manufactured using Physical Property Control Technology for wound care and surgical markets. Products include Hemoleast for hemostasis in massive bleeding punctures, Innoseal for local hemostatic interventions in blood vessels, and Hemo Powder for endoscopic and laparoscopic procedures, along with liquid stents and surgical sealants.
Inno Therapy's top competitors include Adhezion Biomedical, BRIJ Medical and HyperBranch Medical.
Yes, Inno Therapy is publicly traded on KRX under the ticker symbol 246960.
Inno Therapy has 2 investors. Key investors include BSK Investment, and Songhyun Investment.
The ticker symbol of Inno Therapy is 246960 on KRX.